Curie Therapeutics Raises $75 Million Financing To Further Its Mission Of Transforming Cancer Care With Precision Radiopharmaceuticals

Dec 01, 2021•almost 4 years ago

Amount Raised

$75 Million

Cambridge

Description

Curie Therapeutics Inc. ("Curie"), a biotechnology company incubated by Atlas Ventures, Access Biotechnology and RA Capital Management, today announced a Series A investment of $75 million by its founding syndicate to continue the development of its multimodal pipeline of precision radiopharmaceuticals to a broad range of high unmet need solid tumors.

Company Information

Company

Curie Therapeutics

Location

Cambridge, Maryland, United States

About

Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie's mission is to revolutionize the use of radiomedicines in cancer. Learn more at www.curietherapeutics.com

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Curie Therapeutics Raises $75 Million Financing To Further Its Mission Of Transforming Cancer Care With Precision Radiopharmaceuticals

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information